The “Cancer Bush” Sutherlandia (syn. Lessertia) frutescens. An Example of Promotional Research, or Is There Scientific Merit?
Planta Medica · 01.11.2025 · 91 (13) · 730-744
DOI: 10.1055/a-2654-6280 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Planta Medica, erschienen am 01.11.2025. Verfasst von Nicezelle Gernandt und 1 weiteren Autor:innen. Beteiligte Einrichtung: Centre of Excellence for Pharmaceutical Sciences (Pharmacen), North-West University, Potchefstroom, South Africa. Hauptthemen laut MEDLINE: Fabaceae, Neoplasms, Antineoplastic Agents, Phytogenic, Plant Extracts. Die Arbeit nennt 69 Literaturangaben.
Abstract (Originalsprache)
Sutherlandia (syn. Lessertia) frutescens is indigenous to the drier regions of southern Africa. Sutherlandia frutescens has a long history of traditional medicinal use and is credited with antiviral, antibacterial, antifungal, and anticancer properties. It is a very popular phytomedicine and, as the common name implies, is used as a prophylaxis and treatment of cancer. The objective of this review was to collate all published scientific data on the genera Sutherlandia and Lessertia regarding their antiproliferative properties and critically evaluate the data against established guidelines. Despite its use as traditional medicine, the potential of S. frutescens as a cancer treatment remains highly questionable. While in vitro studies suggest some potential antiproliferative effects, many studies lack positive controls and selectivity studies or use excessively high dosages, well above established guidelines, translating into unrealistic clinical applications. Consequently, these studies often appear overly optimistic and biased. Very few well-designed studies are available, and most research fails to meet established guidelines for evaluating selective cytotoxicity. Given these limitations and the absence of rigorous in vivo studies and/or clinical trials, future research may first focus on identifying chemovars with acceptable bioactivity and/or investigating the possibility of the presence of prodrugs by simulated gastrointestinal tract studies. Based on available data, it must be concluded that S. frutescens does not exhibit acceptable levels of bioactivity/selectivity, and keeping in mind possible herb-drug interactions and the serious nature of cancer, which causes over 10 million deaths annually, S. frutescens should not currently be recommended for use.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Centre of Excellence for Pharmaceutical Sciences (Pharmacen), North-West University, Potchefstroom, South Africa.
ORCID-Profile: Frank van der Kooy
Zitieren
APA
Gernandt, N., & van der Kooy, F. (2025). The “Cancer Bush” Sutherlandia (syn. Lessertia) frutescens. An Example of Promotional Research, or Is There Scientific Merit?. Planta Medica, 91(13), 730-744. https://doi.org/10.1055/a-2654-6280
Vancouver
Gernandt N, van der Kooy F. The “Cancer Bush” Sutherlandia (syn. Lessertia) frutescens. An Example of Promotional Research, or Is There Scientific Merit?. Planta Medica. 2025;91(13):730-744. doi:10.1055/a-2654-6280
BibTeX
@article{Gernandt2025,
author = {Gernandt, Nicezelle and van der Kooy, Frank},
title = {The “Cancer Bush” Sutherlandia (syn. Lessertia) frutescens. An Example of Promotional Research, or Is There Scientific Merit?},
journal = {Planta Medica},
year = {2025},
volume = {91},
number = {13},
pages = {730--744},
doi = {10.1055/a-2654-6280}
}
EUVIMED